Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Body mass index (BMI) may not provide the most accurate screening for skeletal muscle deficits among youth with pediatric‐onset inflammatory bowel disease (IBD), according to a study in the Journal of ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

The US FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.